The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Fate Therapeutics
Sponsor:
Information provided by (Responsible Party):
Fate Therapeutics
ClinicalTrials.gov Identifier:
NCT01627314
First received: June 21, 2012
Last updated: June 11, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)